Citations

Clear

4207 citation(s) found for "Chen, Yu".

SpaFlow: a Nextflow pipeline for QC and clustering of MxIF datasets
Novotny, Brenna C. , Moore, Raymond M. , Langit, Lynn, Haley, David, Maus, Rachel L.G., Guo, Ray, Goode, Ellen L. , Ward, Caitlin , Maus, Rachel L, Wang, Chen , Novotny, Brenna , Langit, Lynn, Haley, David, Jiang, Jun , Ward, Caitlin, Guo, Ray, Markovic, Svetomir N.

Mayo Clinic

Bioinformatics Advances | February 14, 2025 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/bioadv/vbaf032 | PMID 40041114 Get It

Abstract Motivation Multiplex immunofluorescence (MxIF) enables the quantification of multiple protein markers at a single-cell level while preserving spatial information, offering a powerful tool for studying tissue microenvironments. However, the flexibility in MxIF panel design poses challenges in standardizing cell phenotyping. Results We present SpaFlow, an efficient, customizable pipeline for unsupervised clustering and classification of MxIF data, implemented using Nextflow. SpaFlow performs quality control, clustering, and postclustering analysis on segmented and quantified MxIF data, facilitating reproducible and scalable analyses across various computing platforms. The SpaFlow pipeline integrates three clustering and classification packages—Seurat, SCIMAP, and CELESTA—each providing unique methodologies for identifying cell types based on phenotypic markers. A novel “meta-clustering” approach condenses clusters across multiple regions of interest into common meta-clusters, streamlining the cell-type identification process in large datasets. SpaFlow’s robust quality control steps, including signal summation and cell density filtering, mitigate artifacts that may impact clustering accuracy. We demonstrate the utility of SpaFlow in a case study involving 297 ovarian tumor cores, where SpaFlow successfully identified biologically meaningful cell populations, including tumor-infiltrating lymphocytes, efficiently and rapidly. Additionally, SpaFlow’s reproducibility is validated using serial tonsil sections, confirming its capability to consistently identify distinctive cell populations across matched ROIs. Availability and implementation SpaFlow is freely available with detailed documentation and examples at https://github.com/dimi-lab/SpaFlow.
Comparative outcomes of arteriovenous malformations treatment in eloquent versus non-eloquent brain: A multicenter study with propensity-score weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Aslan, Assala , Tjoumakaris, Stavropoula I, Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Erginoğlu, Ufuk , Sen, Rajeev , Griessenaur, Christoph, Burkhardt, Jan‐Karl , Starke, Robert M., Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Abla, Adib A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew, Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan , Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael T. , Guthikonda, Bharat , Salim, Hamza , Dmytriw, Adam A , Levitt, Michael R , Chen, Peng R , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Abla, Adib , Altschul, David J , Ogilvy, Christopher S , Alwakaa, Omar , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Mantziaris, Georgios , Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Gooch, Michael Reid , Koch, Matthew J. , Blackburn, Spiros , Kim, Louis J. , Choudhri, Omar , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

International Journal of Stroke | February 14, 2025 | Volume: 20 | Issue: 7 | Pages: 852-863

10.1177/17474930251323503 | PMID 39948730 Get It

Background: Arteriovenous malformations (AVMs) are complex vascular anomalies with a high risk of hemorrhage and neurological deficits, especially when located in eloquent brain regions. The eloquence of an AVM location is a critical factor in the treatment planning, influencing both the risk of complications and long-term functional outcomes. This study aims to compare outcomes between eloquent and non-eloquent AVMs. Methods: This multicenter, retrospective study utilized data from the Multicenter International Study for Treatment of Brain AVMs (MISTA) consortium. Patients with eloquent and non-eloquent AVMs were compared on baseline characteristics, angiographic outcomes, and functional outcomes using the modified Rankin Scale (mRS). Propensity score weighting (IPTW) was applied to adjust for confounding variables. Results: The study included 1013 patients, with 498 (49.2%) AVMs located in eloquent regions and 515 (50.8%) in non-eloquent regions. In unadjusted analysis, eloquent AVMs had lower complete obliteration rates (67.6% vs 79.5%, OR: 0.53, 95% CI: 0.39–0.72, p < 0.001) and higher complication rates (24.5% vs 19.0%, OR: 1.38, 95% CI: 1.02–1.86, p = 0.03) compared to non-eloquent AVMs. After IPTW adjustment, eloquent AVMs continued to show significantly higher odds of overall complications (OR: 1.68, 95% CI: 1.12–2.52, p = 0.01) and symptomatic complications (OR: 1.77, 95% CI: 1.12–2.80, p = 0.01). Secondary analysis within the eloquent group indicated that embolization was linked to an elevated risk of complications. Surgery and radiosurgery showed comparable functional outcomes at last follow-up and complications rates with higher complete obliteration rates in surgery. Conclusion: AVMs in eloquent brain areas present higher risks of complications and lower obliteration rates, emphasizing the need for cautious, individualized treatment planning. Within the eloquent group, embolization increased the risk of complications, while surgery and radiosurgery showed comparable functional outcomes at last follow-up and complication rates with higher complete obliteration rates in surgery. These findings highlight the importance of location in AVM management and support further research focusing on comparing treatment strategies for AVMs in eloquent brain areas.
Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021
Danpanichkul, Pojsakorn , Chen, Vincent , Saokhieo, Preenapun , Dejvajara, Disatorn , Sukphutanan, Banthoon , Lopimpisuth, Chawin , Pang, Yanfang , Fallon, Michael B. , Kim, Donghee , Yang, Ju Dong , Aqel, Bashar , Chen, V L , Saokhieo, Preenapun , Huang, Daniel Q , Kim, Donghee , Singal, Amit , Yang, Ju Dong , Aqel, Bashar A. , Terrault, Norah , Wijarnpreecha, Karn , Danpanichkul, Pojsakorn , Duangsonk, Kwanjit , Aboona, Majd B. , Ibrahim, Andrew , Huang, Daniel Q. , Singal, Amit G. , Terrault, Norah A. , Wijarnpreecha, Karn

Mayo Clinic

Hepatology | February 12, 2025 | Volume: 82 | Issue: 5 | Pages: 1274-1286

10.1097/hep.0000000000001260 | PMID 39937958 Get It

Backgrounds and Aims: HBV-related liver disease ranks as the seventh leading cause of mortality. Despite advances in prevention and treatment, global disparities in the burden of primary liver cancer (PLC) persist. We evaluate global trends in the prevalence, incidence, and death of HBV-related liver disease. Approach and Results: Data from the Global Burden of Disease Study 2021 evaluated acute HBV infection, HBV-related cirrhosis, and HBV-related liver cancer prevalence, incidence, and death. In 2021, there were 7.30 million cases of acute HBV, 283.64 million cases of HBV-related cirrhosis, and 288,110 cases of HBV-related PLC. HBV-related PLC accounted for 39% of the global incidence of PLC; Western Pacific had the highest rates for HBV-related PLC, with an incidence of 5.24 and a death rate of 4.38 per 100,000 population. Between 2000 and 2021, age-standardized incidence, prevalence, and death rates from HBV-related liver disease decreased; however, the incidence of HBV-related PLC rose in 65 countries from 2000 to 2021. In parallel, age-standardized prevalent rates from HBV-related PLC increased in Europe (annual percent change: 0.77%, 95% CI: 0.72%–0.81%) and the Americas (annual percent change: 1.05%, 95% CI: 1.00%–1.10%). Conclusions: From 2000 to 2021, decreases in HBV-related liver disease incidence and prevalence were observed; however, more than one-third of countries showed an increase in the incidence of HBV-related PLC. These findings highlight the need for strengthened HBV treatment efforts to reduce the risk of liver cancer.
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Pazo-Cid, Roberto , Chandana, Sreenivasa R , Dean, Andrew, Leei, Woo Jin, Goetze, Thorsten Oliver , Paulson, Andrew Scott , Bekaii‐Saab, Tanios , Pant, Shubham , Hubner, Richard , Xiao, Zhimin , Chen, Huanyu , Benzaghou, Fawzi, Bekaii-Saab, Tanios S , Wainberg, Zev A. , Melisi, Davide , Macarulla, Teresa , Fouchardière, Christelle de la , Kišš, Igor , Cutsem, Eric Van , Pant, Shubham , O’Reilly, Eileen M.

Mayo Clinic

Future Oncology | February 12, 2025 | Volume: 21 | Issue: 7 | Pages: 765-774

10.1080/14796694.2025.2458458 | PMID 39935331 Get It

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD
Kwon, Young Nam , Tisavipat, Nanthaya , Guo, Yong , Han, Ji Yeon , Kim, Jun‐Soon , Choi, Kyomin , Oh, Seong‐il , Choi, Seok‐Jin , Sohn, Eun Hee , Kim, Seung Woo , Shin, Ha Young , Kim, Byoung Joon , Park, Kyung Seok , Sung, Jung‐Joon , Kim, Se Hoon , Ζεκερίδου, Αναστασία , Lucchinetti, Claudia F. , Pittock, Sean J. , Chen, John J. , Kim, Sung‐Min , Pittock, S J , Syc-Mazurek, Stephanie B , Han, Ji Yeon , Kim, Jun-Soon , Choi, Kyomin , Oh, Seong-Il , Choi, Seok-Jin , Sohn, Eunhee , Oh, Jeeyoung , Kim, Seung Woo , Shin, Ha Young , Lim, Byung Chan , Sung, Jung-Joon , Park, Sung-Hye , Zekeridou, Anastasia , Lucchinetti, Claudia F , Chen, John J , Guo, Yong , Tisavipat, Nanthaya , Syc‐Mazurek, Stephanie B. , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 11, 2025 | Volume: 12 | Issue: 4 | Pages: 861-870

10.1002/acn3.52301 | PMID 39932929 Get It

AbstractCases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77–4.81; P < 0.001) when compared to the age‐ and country‐adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.
Multi-modal AI for Opportunistic Screening, Staging and Progression Risk Stratification of Steatotic Liver Disease
Gao, Yuan , Li, Chun Li, Chang, W., Du, Bai , Ye, Xianghua , Xia, Ying , Liu, Wei , Bai, Ruo Bing, Li, Bei Bei, Hong, Yang , Cao, Kai , Yan, Ke , Li, Chunli , Chang, Wanxing , Du, Bai , Yeo, Yee Hui , Xia, Yingda , Guo, Heng, Zhang, Xiaoming , Bai, Ruobing , Li, Beibei , Hong, Yang , Yao, Jiawen , Lu, Le , Cao, Kai , Yan, Ke , Chen, Jun, Li, Jie , Hou, Yang (Greg), Zhang, Ling , Shi, Yu

Mayo Clinic

No container title available | February 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5783643/v1 Get It

Abstract The prevalence of steatotic liver disease (SLD) is rising globally, presenting a significant public health challenge. While non-contrast computed tomography (CT) scans hold promise for the opportunistic detection of SLD, their full potential has not been systematically explored. Clinical indicators, such as serum data, are crucial for monitoring the progression of SLD. We introduce a novel Multimodal AI for Opportunistic Steatotic Liver Disease Screening (MAOSS), which integrates demographic data, serum tests, conventional CT biomarkers, and deep learning-derived CT image features to enhance model performance and explainability. MAOSS employs an innovative learning strategy, trained on a large-scale dataset (n = 1,783) encompassing both histopathologically-confirmed SLD and radiologically-reported steatosis cases. The model underwent extensive retrospective validation using steatosis grades derived from both histology and MRI-PDFF across internal and external datasets (n = 913), as well as real-world patient data (n = 18,504). It accurately detected mild to severe steatosis (≥ S1) with AUCs ranging from 0.903 to 0.929. Notably, MAOSS significantly improved the overall AUC for radiologists (n = 11) from 0.709 to 0.798 (p < 0.001). Furthermore, MAOSS was applied to optimize the standard clinical pathway for a simulated primary risk screening of SLD patients (n = 1,192), resulting in the identification of 31% more patients at risk of steatohepatitis and liver fibrosis progression, highlighting its potential to enhance SLD detection and management.
Maximizing Lateral Extension of Endoscopic Endonasal Approaches to the Posteromedial Anterior Cranial Fossa: An Anatomical Study
Alexander, A. Yohan , Chen, Sheng , Leonel, Luciano, Celda, María Peris, Alexander, A Yohan , Eide, Jacob G.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803094 Get It

Efficacy and safety of preoperative embolization in surgical treatment of brain arteriovenous malformations: a multicentre study with propensity score matching
Salim, Hamza , Hamdan, Dawoud, Adeeb, Nimer , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S. , Dmytriw, Adam A. , Ataoglu, Cagdas , Erginoğlu, Ufuk , Naamani, Kareem El, Sheehan, Jason P. , Ironside, Natasha , Gummadi, Sanjeev, Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Sen, Rajeev , Başkaya, Mustafa K. , Tjoumakaris, Stavropoula , Atallah, Elias , Riina, Howard A. , Abushehab, Abdallah, Swaid, Christian, Burkhardt, Jan‐Karl , Starke, Robert M., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Abla, Adib A. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward R. , Moehlenbruch, Markus, Alaraj, Ali , Patel, Aman B. , Yedavalli, Vivek , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S , Dmytriw, Adam A , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Jabbour, Pascal , Altschul, David J , Koch, Matthew J , Chen, Peng R , Orbach, Darren B , Alaraj, Ali , Yedavalli, Vivek S , Abla, Adib , Salim, Hamza , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Hamdan, Dawoud , Kandregula, Sandeep , Abdelsalam, Ahmed , Kondziolka, Douglas , Naamani, Kareem El , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Rezai, Arwin, Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Jabbour, Pascal , Sekhar, Laligam N. , Levitt, Michael R. , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Wintermark, Max , Savardekar, Amey Rajan , Morcos, Jacques J.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 6, 2025 | Volume: 96 | Issue: 8 | Pages: 766-774

10.1136/jnnp-2024-334974 | PMID 39915091 Get It

Background Brain arteriovenous malformations (AVMs) are abnormal connections between feeding arteries and draining veins, associated with significant risks of haemorrhage, seizures and other neurological deficits. Preoperative embolization is commonly used as an adjunct to microsurgical resection, with the aim of reducing intraoperative complications and improving outcomes. However, the efficacy and safety of this approach remain controversial. Methods This study is a subanalysis of the Multicenter International Study for Treatment of Brain AVMs consortium. We retrospectively analysed 486 patients with brain AVMs treated with microsurgical resection between January 2010 and December 2023. Patients were divided into two groups: those who underwent microsurgery alone (n=245) and those who received preoperative embolization, followed by microsurgery (n=241). Propensity score matching was employed, resulting in 288 matched patients (144 in each group). The primary outcomes were rates of complete AVM obliteration and functional outcomes (measured by the modified Rankin Scale (mRS)). Secondary outcomes included complication rates, mortality, hospital length of stay and postsurgical rupture. Results After matching, the complete obliteration rate was 97% with no significant difference between the microsurgery-only group and the preoperative embolization group (p=0.12). The proportion of patients with an mRS score of 0–2 at the last follow-up was similar in both groups (83% vs 84%; p=0.67). The median hospital stay was significantly longer for the embolisation group (9 days vs 7 days; p=0.017). Complication rates (24% vs 22%; p=0.57) and mortality rates (4.9% vs 2.1%; p=0.20) were comparable between the two groups. No significant differences were observed in postsurgical rupture, recurrence or retreatment rates. Conclusions In this large multicentre study, preoperative embolization did not significantly improve AVM obliteration rates, functional outcomes or reduce complications compared with microsurgery alone.
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion
Goyal, Mayank , Möhlenbruch, Markus , Nimjee, Shahid M. , Buck, Brian , Kennedy, James , Zhang, Liqun , Hametner, Christian , Nardai, Sándor , Zafar, Atif , Diprose, William K. , Vatanpour, Shabnam , Stebner, Alexander, Bosshart, Salome , Uchida, Kazutaka , Ryckborst, Karla J., Fahed, Robert, Hu, Sherry , Zaidi, Syed , Lee, Vivien , Teal, Rachel, Trivedi, Anurag , Ogungbemi, Ayokunle, Orosz, Péter , Abdalkader, Mohamad , Taschner, Christian , Tarpley, Jason , Poli, Sven , Sahlas, Demetrios J. , Burns, Paul , Marigold, Richard , Amole, Adewumi, Field, Thalia S. , Settecase, Fabio , Lenzsér, Gábor, Asdaghi, Negar , Lobotesis, Kyriakos , Siddiqui, Adnan H. , Berrouschot, J., Ebersole, Koji , Schneider, Hauke , Mandzia, Jennifer, Klostranec, Jesse , Jadun, Changez, Patankar, Tufail , Sauvageau, Eric , Lenthall, Robert , Peeling, Lissa, Budzik, Ronald F. , Lee, Seon-Kyu, Perry, Richard , Hlaing, Thant , Singh, Paul, Hill, Michael D. , Vakharia, Kunal , Harston, George , Möhlenbruch, Markus A , Nimjee, Shahid M , Buck, Brian H , Kennedy, James , Zhang, Liqun , Hametner, Christian , Diprose, William , Vatanpour, Shabnam , Stebner, Alexander , Bosshart, Salome , Singh, Nishita , Hu, Sherry X , Vollherbst, Dominik F , Lee, Vivien H , Rempel, Jeremy L , Teal, Rachel , Trivedi, Anurag , Bode, Felix J , Abdalkader, Mohamad , Poli, Sven , Singh, Ravinder-Jeet , Lopez, George , Schaafsma, Joanna D , Marigold, Richard , Field, Thalia S , Settecase, Fabio , Ortega-Gutierrez, Santiago , Mokin, Maxim , Ebersole, Koji , Schneider, Hauke , Yoo, Albert J , Klostranec, Jesse , Lenthall, Robert , Huynh, Thien , Budzik, Ronald , Levitt, Michael R , Jahromi, Babak S , Hill, Michael D , Siddiqui, Adnan H , Ospel, Johanna M. , Ganesh, Aravind , Dowlatshahi, Dar , Volders, David , Jumaa, Mouhammad , Booth, Thomas Calvert , Shankar, Jai , Dorn, Franziska , Sebastian, Ivy Anne , Fahed, Robert , Lynch, Jeremy , Bode, Felix J. , Pham, Mirko , Leacy, Reade De , Chen, Michael , Reich, Arno , Swartz, Richard H. , Yoo, Albert J. , Huynh, Thien , Makalanda, Levansri , Levitt, Michael R. , Jahromi, Babak S. , Demchuk, Andrew M.

Mayo Clinic

New England Journal of Medicine | February 5, 2025 | Volume: 392 | Issue: 14 | Pages: 1385-1395

10.1056/nejmoa2411668 | PMID 39908448 Get It

Real‐world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell‐based assay
Said, Yana , Filippatou, Angeliki , Tran, Conlan , Rezavi, LuAnn, Guo, Kai , Resto, Yasmin, Chen, John J. , Pittock, Sean J. , Sotirchos, Elias S. , Pittock, S J , Calabresi, Peter A , Sotirchos, Elias S , Chen, John J , Said, Yana , Filippatou, Angeliki G , Smith, Matthew D. , Calabresi, Peter A. , Caturegli, Patrizio , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 4, 2025 | Volume: 12 | Issue: 3 | Pages: 556-564

10.1002/acn3.52310 | PMID 39901660 Get It

Abstract Objective To assess the real‐world performance of a live (LCBA) versus a fixed (FCBA) cell‐based assay for the detection of serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG‐IgG) and aquaporin‐4 (AQP4‐IgG). Methods This was a retrospective study of patients evaluated at a single tertiary academic referral center, with serum testing performed clinically for AQP4‐IgG and/or MOG‐IgG by FCBA and LCBA on the same day. Additionally, frozen banked sera from the same day for patients tested only by one assay were retrieved and tested by the other assay. FCBA was performed by the Johns Hopkins Immunology Laboratory using Euroimmun kits with detection by indirect immunofluorescence (FCBA‐IF), whereas LCBA was performed by the Mayo Clinic Neuroimmunology Laboratory with detection by flow cytometry (LCBA‐FACS). Results Of 594 specimens with paired MOG‐IgG testing, 500 were negative by both assays, 33 were positive by both assays, 56 were positive exclusively by LCBA‐FACS, and 5 were only positive by FCBA‐IF. Overall, MOG‐IgG LCBA‐FACS exhibited 95.1% sensitivity and 97.7% specificity, whereas MOG‐IgG FCBA‐IF had 45.7% sensitivity and 99.8% specificity. Of 577 specimens with paired AQP4‐IgG testing, 503 were negative by both assays, 51 were positive by both assays, 21 were positive exclusively by LCBA‐FACS, and 2 were only positive by FCBA‐IF. Overall, AQP4‐IgG LCBA‐FACS exhibited 97.3% sensitivity and 100% specificity, whereas AQP4‐IgG FCBA‐IF had 71.6% sensitivity and 100% specificity. Interpretation LCBA‐FACS for both MOG‐IgG and AQP4‐IgG had markedly better sensitivity than FCBA‐IF, with similar specificity. The use of FCBA‐IF may result in underrecognition of both MOG antibody‐associated disease (MOGAD) and AQP4‐IgG seropositive neuromyelitis optica spectrum disorder (NMOSD).